Casdin Capital to Become Shareholder in BioLife Solutions

BOTHELL, Wash., April 9, 2018 /PRNewswire/ — BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade biopreservation media, ("BioLife" or the "Company"), today announced that Casdin Capital LLC, ("Casdin") a New York-based, life science-focused investment firm, has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company's second largest shareholder, who has been a primary source of investment capital for the Company since its inception.

Mike Rice, BioLife CEO commented, "We extend a warm welcome to Casdin Capital as a new long term institutional investor. Casdin's long term investment thesis recognizes the enormous medical and investment impact of cellular medicine, including the role of the ecosystem of embedded tools providers, and as such is well aligned with our mission to become the leading provider of biopreservation tools for cells, tissues and organs."



About Casdin Capital

Casdin Capital LLC ("Casdin"), a NYC-based Life Science investment firm founded in 2012, brings a deep understanding, expertise and long term perspective to financing the next generation of life science innovation. For more information please visit https://www.casdincapital.com.



Media & Investor Relations 
Roderick de Greef 
Chief Financial Officer
(425) 686-6003 
rdegreef@biolifesolutions.com
 

SOURCE BioLife Solutions, Inc.

 

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

BioLife Solutions

BioLife Solutions is the leading developer, manufacturer and supplier of proprietary, clinical-grade biopreservation media for cells and tissues. Our HypoThermosol® hypothermic storage and CryoStor®cryopreservation freeze media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death; offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function. 

Q: